Hinova Pharmaceuticals (SHSE:688302) EV-to-EBIT : -6.32 (As of Jun. 22, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Hinova Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Hinova Pharmaceuticals's Enterprise Value is ¥1,671.59 Mil. Hinova Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-264.70 Mil. Therefore, Hinova Pharmaceuticals's EV-to-EBIT for today is -6.32.

The historical rank and industry rank for Hinova Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

SHSE:688302' s EV-to-EBIT Range Over the Past 10 Years
Min: -20.9 Med: -10.78 Max: -4.18
Current: -6.31

During the past 6 years, the highest EV-to-EBIT of Hinova Pharmaceuticals was -4.18. The lowest was -20.90. And the median was -10.78.

SHSE:688302's EV-to-EBIT is ranked worse than
100% of 438 companies
in the Biotechnology industry
Industry Median: 8.76 vs SHSE:688302: -6.31

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Hinova Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was ¥2,044.88 Mil. Hinova Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-264.70 Mil. Hinova Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -12.94%.

Hinova Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Hinova Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hinova Pharmaceuticals EV-to-EBIT Chart

Hinova Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-8.27

-13.89

Hinova Pharmaceuticals Quarterly Data
	Dec18	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial												-13.61	-12.67	-10.20	-13.89	-7.73

Competitive Comparison of Hinova Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Hinova Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hinova Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hinova Pharmaceuticals's EV-to-EBIT falls into.

Hinova Pharmaceuticals EV-to-EBIT Calculation

Hinova Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1671.587	/	-264.698
	=	-6.32

Hinova Pharmaceuticals's current Enterprise Value is ¥1,671.59 Mil.
Hinova Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-264.70 Mil.

Hinova Pharmaceuticals (SHSE:688302) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Hinova Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-264.698	/	2044.875792
	=	-12.94 %

Hinova Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was ¥2,044.88 Mil.
Hinova Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-264.70 Mil.

Hinova Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Hinova Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Hinova Pharmaceuticals (SHSE:688302) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hinova Pharmaceuticals Inc (SHSE:688302) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 5 Keyuan South Road, No. 2 and 3, 4th Floor, Building 1, Rongyao Building, High-tech Zone, Sichuan Province, Chengdu, CHN, 610041

Website

http://www.hinovapharma.com

Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.

Hinova Pharmaceuticals (SHSE:688302) Headlines

No Headlines